- Home
- OM vs IMMP Comparison
OM vs IMMP Comparison
Compare OM & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- IMMP
- Stock Information
- Founded
- OM 2003
- IMMP 1987
- Country
- OM United States
- IMMP Australia
- Employees
- OM N/A
- IMMP N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- IMMP Health Care
- Exchange
- OM Nasdaq
- IMMP Nasdaq
- Market Cap
- OM 305.5M
- IMMP 251.8M
- IPO Year
- OM 2020
- IMMP N/A
- Fundamental
- Price
- OM $19.42
- IMMP $1.60
- Analyst Decision
- OM Buy
- IMMP Buy
- Analyst Count
- OM 2
- IMMP 1
- Target Price
- OM $33.00
- IMMP $7.00
- AVG Volume (30 Days)
- OM 288.3K
- IMMP 97.6K
- Earning Date
- OM 08-06-2025
- IMMP 02-27-2025
- Dividend Yield
- OM N/A
- IMMP N/A
- EPS Growth
- OM N/A
- IMMP N/A
- EPS
- OM N/A
- IMMP N/A
- Revenue
- OM $115,273,000.00
- IMMP $3,019,249.00
- Revenue This Year
- OM $10.80
- IMMP $50.37
- Revenue Next Year
- OM $11.99
- IMMP N/A
- P/E Ratio
- OM N/A
- IMMP N/A
- Revenue Growth
- OM N/A
- IMMP 24.11
- 52 Week Low
- OM $5.85
- IMMP $1.32
- 52 Week High
- OM $72.60
- IMMP $2.80
- Technical
- Relative Strength Index (RSI)
- OM 57.31
- IMMP 34.41
- Support Level
- OM $18.62
- IMMP $1.81
- Resistance Level
- OM $20.80
- IMMP $1.92
- Average True Range (ATR)
- OM 1.39
- IMMP 0.08
- MACD
- OM -0.30
- IMMP -0.03
- Stochastic Oscillator
- OM 53.62
- IMMP 0.00
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.